Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion

Derrell M. Wilson, Susan N. Perkins, James A. Thomas, Steven Seelig, Susan A. Berry, Thomas E. Hamm, Andrew R. Hoffman, Raymond L. Hintz, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The insulinlike growth factors (IGF) appear to exert feedback control over their own production. In an effort to determine the physiologic mechanisms for this feedback modulation, we utilized a previously developed in vivo model in which rIGF-II secreting tumor cells are transplanted into immunodeficient rats to form IGF-II secreting tumors. The tumor-bearing rat have serum IGF-II concentrations sevenfold greater than those in controls (119 ± 16 ng/mL [mean ± SE] v 17 ± 2 ng/mL, P <.0001). Serum IGF-I concentrations were reduced among the tumor-bearing rats (438 ± 42 ng/mL v 606 ± 32 ng/mL, P = .002) and were negatively correlated with IGF-II concentrations (r = -.47, P = .025), suggesting that IGF-II suppressed the secretion of IGF-I. Increased serum IGF-II concentrations, however, did not affect basal growth hormone concentrations (tumor-bearing, 44 ± 12 ng/mL; control 33 ± 6 ng/mL, P = 0.96). The GH response to GH releasing factor was likewise similar in both groups. Moveover, pituitary GH mRNA level were not different in the two groups, suggesting that IGF-II does not have a significant effect on GH secretion in this in vivo model. There was no association between serum glucose and serum IGF-I or IGF-II concentrations. To examine the effect of IGF-II on IGF-I production from the liver, we measured IGF-I mRNA levels in a subset of animals. Despite these differences in serum IGF-I concentrations, the tumor-bearing rats did not have significantly lower liver IGF-I mRNA levels. These data suggest that IGF-II may act at sites other than the pituitary or liver to alter serum IGF-I concentrations.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalMetabolism
Volume38
Issue number1
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Growth Hormone
Intercellular Signaling Peptides and Proteins
Messenger RNA
Serum
Neoplasms
Liver

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Wilson, D. M., Perkins, S. N., Thomas, J. A., Seelig, S., Berry, S. A., Hamm, T. E., ... Rosenfeld, R. R. (1989). Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion. Metabolism, 38(1), 57-62. https://doi.org/10.1016/0026-0495(89)90180-7

Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion. / Wilson, Derrell M.; Perkins, Susan N.; Thomas, James A.; Seelig, Steven; Berry, Susan A.; Hamm, Thomas E.; Hoffman, Andrew R.; Hintz, Raymond L.; Rosenfeld, Ronald (Ron).

In: Metabolism, Vol. 38, No. 1, 1989, p. 57-62.

Research output: Contribution to journalArticle

Wilson, DM, Perkins, SN, Thomas, JA, Seelig, S, Berry, SA, Hamm, TE, Hoffman, AR, Hintz, RL & Rosenfeld, RR 1989, 'Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion', Metabolism, vol. 38, no. 1, pp. 57-62. https://doi.org/10.1016/0026-0495(89)90180-7
Wilson, Derrell M. ; Perkins, Susan N. ; Thomas, James A. ; Seelig, Steven ; Berry, Susan A. ; Hamm, Thomas E. ; Hoffman, Andrew R. ; Hintz, Raymond L. ; Rosenfeld, Ronald (Ron). / Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion. In: Metabolism. 1989 ; Vol. 38, No. 1. pp. 57-62.
@article{e4fa7d7a81b440019da5090f6d072b5e,
title = "Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion",
abstract = "The insulinlike growth factors (IGF) appear to exert feedback control over their own production. In an effort to determine the physiologic mechanisms for this feedback modulation, we utilized a previously developed in vivo model in which rIGF-II secreting tumor cells are transplanted into immunodeficient rats to form IGF-II secreting tumors. The tumor-bearing rat have serum IGF-II concentrations sevenfold greater than those in controls (119 ± 16 ng/mL [mean ± SE] v 17 ± 2 ng/mL, P <.0001). Serum IGF-I concentrations were reduced among the tumor-bearing rats (438 ± 42 ng/mL v 606 ± 32 ng/mL, P = .002) and were negatively correlated with IGF-II concentrations (r = -.47, P = .025), suggesting that IGF-II suppressed the secretion of IGF-I. Increased serum IGF-II concentrations, however, did not affect basal growth hormone concentrations (tumor-bearing, 44 ± 12 ng/mL; control 33 ± 6 ng/mL, P = 0.96). The GH response to GH releasing factor was likewise similar in both groups. Moveover, pituitary GH mRNA level were not different in the two groups, suggesting that IGF-II does not have a significant effect on GH secretion in this in vivo model. There was no association between serum glucose and serum IGF-I or IGF-II concentrations. To examine the effect of IGF-II on IGF-I production from the liver, we measured IGF-I mRNA levels in a subset of animals. Despite these differences in serum IGF-I concentrations, the tumor-bearing rats did not have significantly lower liver IGF-I mRNA levels. These data suggest that IGF-II may act at sites other than the pituitary or liver to alter serum IGF-I concentrations.",
author = "Wilson, {Derrell M.} and Perkins, {Susan N.} and Thomas, {James A.} and Steven Seelig and Berry, {Susan A.} and Hamm, {Thomas E.} and Hoffman, {Andrew R.} and Hintz, {Raymond L.} and Rosenfeld, {Ronald (Ron)}",
year = "1989",
doi = "10.1016/0026-0495(89)90180-7",
language = "English (US)",
volume = "38",
pages = "57--62",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion

AU - Wilson, Derrell M.

AU - Perkins, Susan N.

AU - Thomas, James A.

AU - Seelig, Steven

AU - Berry, Susan A.

AU - Hamm, Thomas E.

AU - Hoffman, Andrew R.

AU - Hintz, Raymond L.

AU - Rosenfeld, Ronald (Ron)

PY - 1989

Y1 - 1989

N2 - The insulinlike growth factors (IGF) appear to exert feedback control over their own production. In an effort to determine the physiologic mechanisms for this feedback modulation, we utilized a previously developed in vivo model in which rIGF-II secreting tumor cells are transplanted into immunodeficient rats to form IGF-II secreting tumors. The tumor-bearing rat have serum IGF-II concentrations sevenfold greater than those in controls (119 ± 16 ng/mL [mean ± SE] v 17 ± 2 ng/mL, P <.0001). Serum IGF-I concentrations were reduced among the tumor-bearing rats (438 ± 42 ng/mL v 606 ± 32 ng/mL, P = .002) and were negatively correlated with IGF-II concentrations (r = -.47, P = .025), suggesting that IGF-II suppressed the secretion of IGF-I. Increased serum IGF-II concentrations, however, did not affect basal growth hormone concentrations (tumor-bearing, 44 ± 12 ng/mL; control 33 ± 6 ng/mL, P = 0.96). The GH response to GH releasing factor was likewise similar in both groups. Moveover, pituitary GH mRNA level were not different in the two groups, suggesting that IGF-II does not have a significant effect on GH secretion in this in vivo model. There was no association between serum glucose and serum IGF-I or IGF-II concentrations. To examine the effect of IGF-II on IGF-I production from the liver, we measured IGF-I mRNA levels in a subset of animals. Despite these differences in serum IGF-I concentrations, the tumor-bearing rats did not have significantly lower liver IGF-I mRNA levels. These data suggest that IGF-II may act at sites other than the pituitary or liver to alter serum IGF-I concentrations.

AB - The insulinlike growth factors (IGF) appear to exert feedback control over their own production. In an effort to determine the physiologic mechanisms for this feedback modulation, we utilized a previously developed in vivo model in which rIGF-II secreting tumor cells are transplanted into immunodeficient rats to form IGF-II secreting tumors. The tumor-bearing rat have serum IGF-II concentrations sevenfold greater than those in controls (119 ± 16 ng/mL [mean ± SE] v 17 ± 2 ng/mL, P <.0001). Serum IGF-I concentrations were reduced among the tumor-bearing rats (438 ± 42 ng/mL v 606 ± 32 ng/mL, P = .002) and were negatively correlated with IGF-II concentrations (r = -.47, P = .025), suggesting that IGF-II suppressed the secretion of IGF-I. Increased serum IGF-II concentrations, however, did not affect basal growth hormone concentrations (tumor-bearing, 44 ± 12 ng/mL; control 33 ± 6 ng/mL, P = 0.96). The GH response to GH releasing factor was likewise similar in both groups. Moveover, pituitary GH mRNA level were not different in the two groups, suggesting that IGF-II does not have a significant effect on GH secretion in this in vivo model. There was no association between serum glucose and serum IGF-I or IGF-II concentrations. To examine the effect of IGF-II on IGF-I production from the liver, we measured IGF-I mRNA levels in a subset of animals. Despite these differences in serum IGF-I concentrations, the tumor-bearing rats did not have significantly lower liver IGF-I mRNA levels. These data suggest that IGF-II may act at sites other than the pituitary or liver to alter serum IGF-I concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0024540366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024540366&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(89)90180-7

DO - 10.1016/0026-0495(89)90180-7

M3 - Article

C2 - 2491900

AN - SCOPUS:0024540366

VL - 38

SP - 57

EP - 62

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 1

ER -